TrialNature communications2024

Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1/2 trial.

Anders Kvanta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.